



HEALTHCARE

The Pain Management Market Outlook To 2014

Competitive landscape, pipeline analysis and growth opportunities

By Business Insights

Copyright © 2009 Business Insights Ltd
This Management Report is published by Business Insights Ltd. All rights reserved.
Reproduction or redistribution of this Management Report in any form for any
purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of
Business Insights. Business Insights Ltd accepts no liability for the accuracy or
completeness of the information, advice or comment contained in this Management
Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of
publication, no responsibility can be accepted by Business Insights Ltd for its
completeness or accuracy.

Table of Contents

The Pain Management Market Outlook to 2014

Executive Summary	12	
Overview and epidemiology of pain	12	
Global market analysis	13	
Pipeline analysis	14	
Competitive landscape	15	
Chapter 1	Scope and methodology	18
Scope		18
Methodology		18
Chapter 2	Overview and epidemiology of pain	22
Summary		22
Introduction		23
Neuropathic pain		26
Lower back pain		26
Background		26
Diagnosis, treatment and management		27
Epidemiology		29
Neuralgia/fibromyalgia		31
Background		31
Diagnosis, treatment and management		32
Epidemiology		32
Diabetic neuropathic pain		35
Background		35
Diagnosis, treatment and management		35
Epidemiology		37
Pain associated with multiple sclerosis		39
Background		39

	Diagnosis, treatment and management	40
	Epidemiology	41
Nociceptive pain		43
Arthritic pain		43
	Background	43
	Diagnosis, treatment and management	44
	Epidemiology	45
Post-operative pain		49
	Background	49
	Diagnosis, treatment and management	49
	Epidemiology	50
Cancer-related pain		52
	Background	52
	Diagnosis, treatment and management	52
	Epidemiology	53
HIV/AIDS-related pain		57
	Background	57
	Diagnosis, treatment and management	57
	Epidemiology	58

Chapter 3 Global market analysis 62

Summary		62
Introduction		63
Key events		63
	Revival of Mundipharma's OxyContin CR sales followin out-of-court settlements	63
	Mylan's fentanyl patches may succeed where J&J's Duragesic failed	64
	OGD loosens requirements for generic lidocaine patches	65
	M&A and licensing deals to drive the global pain management market	65
Regional dynamics		67
Market analysis by drug class		68
Leading brands in the global pain market		69
Analgesics		71
	Analgesics market analysis by drug class	72
	Leading brands in the analgesics market	73
	Leading players in the analgesics market	75
	Analgesic drug classes	76
	Narcotic analgesics	76
	Non-narcotic analgesics	86
	Analgesics sales forecasts	91
Anticonvulsants		91
	Leading brands in the anticonvulsants market	93
	Leading players in the anticonvulsants market	105

Anticonvulsants sales forecasts	106
Non-steroidal anti-inflammatory drugs	107
NSAIDs market analysis by drug class	108
Leading brands in the NSAIDs market	109
Leading players in the NSAIDs market	111
NSAID classes	112
Anti-rheumatic NSAIDs	112
Coxibs	117
NSAIDs sales forecasts	123
Local anesthetics	123
Local anesthetics market analysis by medical applications	124
Leading brands in the local anesthetics market	125
Leading players in the local anesthetics market	129
Local anesthetics sales forecasts	130
Global pain management sales forecasts	131

Chapter 4 Pipeline analysis 134

Summary	134
Introduction	135
R&D trends	136
Reduced R&D activity from leading drug companies	136
Innovative drug delivery formulations and reformulations	137
Development of products associated with better side effect profiles	137
Flexibility in titration and dosing	137
Entry of biologics into the pain management space	137
Trial data bridging may reduce the number of studies required for EU approval	138
Leading products in development	139
New chemical entities	140
Tapentadol	140
Tanezumab	142
Naproxcinod	144
Ralfinamide	146
Novel formulations	148
Remoxy	148
Embeda	150
Onsolis	152
Diractin	154
Rapinyl/Abstral	156
Eladur	159
Pipeline sales forecasts	160

Chapter 5 Competitive landscape 162

Summary		162
Introduction		163
Sales performance of leading players		164
Forecast sales performance of the leading players		166
Pfizer		167
	Overview	167
	Drug class focus	168
	Key brands	169
	Pipeline portfolio	171
	Strategic and growth analysis	172
J&J		173
	Overview	173
	Drug class focus	174
	Key brands	175
	Pipeline portfolio	177
	Strategic and growth analysis	177
Novartis		179
	Overview	179
	Drug class focus	180
	Key brands	181
	Strategic and growth analysis	182
GlaxoSmithKline		184
	Overview	184
	Drug class focus	184
	Key brands	186
	Strategic and growth analysis	187
Mundipharma		188
	Overview	188
	Drug class focus	189
	Key brands	190
	Strategic and growth analysis	191
Abbott		192
	Overview	192
	Drug class focus	192
	Key brands	193
	Strategic and growth analysis	194
Sanofi-Aventis		195
	Overview	195
	Drug class focus	196
	Key brands	197
	Strategic and growth analysis	198
UCB		199
	Overview	199
	Drug class focus	199
	Key brands	200
	Strategic and growth analysis	201
Teva		201

	Overview	201
	Drug class focus	202
	Key brands	203
	Strategic and growth analysis	204
Endo Pharma		205
	Overview	205
	Drug class focus	206
	Licensing deals	206
	Key brands	208
	Strategic and growth analysis	209

Chapter 6 Appendix 212

IMS Data		212
	M1A1 Antirheumatics non-steroidal plain	212
	M1A2 Antirheumatics non-steroidal combination	212
	M1A3 Coxibs plain	212
	N1B1 Anesthetics local medical injection	212
	N1B2 Anaesthetics local dental injection	212
	N1B3 Anaesthetics local topical	212
	N1B9 Anaesthetics local others	212
	N2A0 Narcotic analgesics	213
	N2B0 Non-narcotic analgesics	213
	N2B1 Non-narcotic analgesics, prescription	213
	N2B2 Non-narcotic analgesics, OTC	213
	N3A0 Anti-epileptics	213
Glossary		214
Index		216

List of Figures

Figure 2.1:	Factors involved in pain sensation	24
Figure 3.2:	Regional shares (%) of the pain management market, 2007	67
Figure 3.3:	Clinical profile of OxyContin CR	80
Figure 3.4:	Clinical profile of Duragesic	84
Figure 3.5:	Clinical profile of Topamax	95
Figure 3.6:	Clinical profile of Lamictal	99
Figure 3.7:	Clinical profile of Lyrica	103
Figure 3.8:	Clinical profile of Voltaren	115
Figure 3.9:	Clinical profile of Celebrex	120
Figure 3.10:	Clinical profile of Lidoderm	127
Figure 4.11:	Leading recently launched products and late-stage R&D compounds indicated for the treatment of pain, 2009	139
Figure 4.12:	“Abuse-deterrent” formulation design of Embeda	151
Figure 5.13:	Market dynamics of leading players in the global pain management market, 2006–07	165

List of Tables

Table 2.1:	Estimated prevalence of neuropathic and nociceptive pain in the seven major pharmaceutical markets, 2008	25
Table 2.2:	Estimated prevalence of neuropathic lower back pain in the seven major pharmaceutical markets, 2008	29
Table 2.3:	Forecast prevalence of neuropathic lower back pain across the seven major markets, 2008–14	30
Table 2.4:	Estimated prevalence of neuralgia/fibromyalgia pain in the seven major pharmaceutical markets, 2008	33
Table 2.5:	Forecast prevalence of neuralgia/fibromyalgia across the seven major markets, 2008–14	34
Table 2.6:	Estimated prevalence of diabetic neuropathic pain in the seven major pharmaceutical markets, 2008	37
Table 2.7:	Forecast prevalence of diabetic neuropathic pain across the seven major markets, 2008–14	38
Table 2.8:	Estimated prevalence of multiple sclerosis in the seven major pharmaceutical markets, 2008	41
Table 2.9:	Forecast prevalence of pain associated with multiple sclerosis across the seven major markets, 2008–14	42
Table 2.10:	Estimated prevalence of OA-related pain in the seven major pharmaceutical markets, 2008	45
Table 2.11:	Estimated prevalence of RA pain in the seven major pharmaceutical markets, 2008	46
Table 2.12:	Forecast prevalence of OA-related pain across the seven major markets, 2008–14	47
Table 2.13:	Forecast prevalence of RA-related pain across the seven major markets, 2008–14	48

Table 2.14:	Estimated prevalence of post-operative pain in the seven major pharmaceutical markets, 2008	50
Table 2.15:	Forecast prevalence of post-operative pain across the seven major markets, 2008–14	51
Table 2.16:	Estimated prevalence of cancer-related pain in the seven major pharmaceutical markets, 2008	54
Table 2.17:	Forecast prevalence of early-stage cancer-related pain across the seven major markets, 2008–14	55
Table 2.18:	Forecast prevalence of late-stage cancer-related pain across the seven major markets, 2008–14	56
Table 2.19:	Estimated prevalence of HIV/AIDS-related neuropathic pain in the seven major pharmaceutical markets, 2008	58
Table 2.20:	Forecast prevalence of HIV/AIDS-related pain across the seven major markets, 2008–14	59
Table 3.21:	Licensing deals in the global pain management market	66
Table 3.22:	Break-up of the global pain management market by drug class, 2006–07	68
Table 3.23:	Leading brands in the global pain management market, 2006–07	70
Table 3.24:	Drug classes in the global analgesics market, 2006–07	72
Table 3.25:	Leading brands in the global analgesics market, 2006–07	73
Table 3.26:	Leading players in the global analgesics market, 2006–07	75
Table 3.27:	Leading brands in the global narcotic analgesics market, 2006–07	78
Table 3.28:	Leading brands in the global non-narcotic analgesics market, 2006–07	88
Table 3.29:	Competitive analysis of Tylenol and Efferalgan	90
Table 3.30:	Sales forecasts of analgesics, 2007–14	91
Table 3.31:	Leading brands in the global anticonvulsants market, 2006–07	93
Table 3.32:	Leading anticonvulsant brands based on proportion of sales generated by prescriptions for pain indications in the seven major markets, 2007	94
Table 3.33:	Leading players in the global anticonvulsants market, 2006–07	105
Table 3.34:	Sales forecast for the anticonvulsants, 2007–14	106
Table 3.35:	Drug classes in the global NSAIDs market, 2006–07	108
Table 3.36:	Leading brands in the global NSAIDs market, 2006–07	109
Table 3.37:	Leading players in the global NSAIDs market, 2006–07	111
Table 3.38:	Leading brands in the global anti-rheumatic NSAIDs market, 2006–07	113
Table 3.39:	Leading brands in the global coxibs market, 2006–07	118
Table 3.40:	Sales forecasts of NSAIDs, 2007–14	123
Table 3.41:	Medical applications in the global local anesthetics market, 2006–07	124
Table 3.42:	Leading brands in the global local anesthetics market, 2006–07	125
Table 3.43:	Leading players in the global local anesthetics market, 2006–07	129
Table 3.44:	Sales forecasts of local anesthetics, 2007–14	130
Table 3.45:	Sales forecasts of the global pain management market, 2007–14	131
Table 4.46:	An overview of tapentadol	140
Table 4.47:	An overview of tanezumab	142
Table 4.48:	An overview of naproxcinod	144
Table 4.49:	An overview of ralfinamide	146
Table 4.50:	An overview of Remoxy	148
Table 4.51:	An overview of Embeda	150
Table 4.52:	An overview of Onsolis	152
Table 4.53:	An overview of Diractin	154
Table 4.54:	An overview of Rapinyl/Abstral	156
Table 4.55:	An overview of Eladur	159
Table 4.56:	Sales forecasts of pipeline compounds, 2007–14	160
Table 5.57:	Leading companies in the global pain management market,	164
Table 5.58:	Pain management sales forecasts of the leading players in the market, 2007–14	166
Table 5.59:	Pfizer's pain management sales break-up based on drug class, 2007	168

Table 5.60:	Pfizer's leading pain management products, 2006–07	169
Table 5.61:	Pfizer's key pain management products under development, March 2009	171
Table 5.62:	J&J's pain management sales break-up based on drug class, 2007	174
Table 5.63:	J&J's leading pain management products, 2006–07	175
Table 5.64:	J&J's key pain management products under development,	177
Table 5.65:	Novartis's pain management sales break-up based on drug class, 2007	180
Table 5.66:	Novartis's leading pain management products, 2006–07	181
Table 5.67:	GSK's pain management sales break-up based on drug class, 2007	184
Table 5.68:	GSK's leading pain management products, 2006–07	186
Table 5.69:	Mundipharma's pain management sales break-up based on drug class, 2007	189
Table 5.70:	Mundipharma's leading pain management products, 2006–07	190
Table 5.71:	Abbott's pain management sales break-up based on drug class, 2007	192
Table 5.72:	Abbott's leading pain management products, 2006–07	193
Table 5.73:	Sanofi-Aventis's pain management sales break-up based on drug class, 2007	196
Table 5.74:	Sanofi-Aventis's leading pain management products, 2006–07	197
Table 5.75:	UCB's pain management sales break-up based on drug class, 2007	199
Table 5.76:	UCB's leading pain management products, 2006–07	200
Table 5.77:	Teva's pain management sales break-up based on drug class, 2007	202
Table 5.78:	Teva's leading pain management products, 2006–07	203
Table 5.79:	Endo's pain management sales break-up based on drug class, 2007	206
Table 5.80:	Endo's US pain management marketing licensing deals	207
Table 5.81:	Endo's leading pain management products, 2006–07	208